In the pivotal phase III GOLD trial, 284 patients with advanced RCC who received one previous VEGF-targeted therapy and one previous mTOR inhibitor were randomized to receive either dovitinib (at dose of 500 mg orally, five days on and two days off) or sorafenib (at dose of 400 mg orally twice daily) [34]. This evidence concerns the gene MTOR and renal cell carcinoma.